1
|
López-Enríquez S, Porras-González C, Moreno-Luna R, Palomares F, Muñoz-Bravo JL, Alba G, Santa-María C, Maza-Solano J, Martín-Jiménez DI, Pérez-Pérez A, Moreno-Luna R, Sánchez-Margalet V, Sánchez-Gómez S. Tissue-specific early and late activated lymphocytes immunophenotype in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2024; 14:1245-1248. [PMID: 38268107 DOI: 10.1002/alr.23327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 12/27/2023] [Accepted: 01/04/2024] [Indexed: 01/26/2024]
Abstract
KEY POINTS T-cell activation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is enriched by late cytotoxic T cells. The proportion of early and intermediate activated cytotoxic T cells decreases in nasal polyps of patients with CRSwNP. Our results identify late activated cytotoxic T cells as potential biomarkers or therapeutic targets for patients with CRSwNP.
Collapse
Affiliation(s)
- Soledad López-Enríquez
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
| | - Cristina Porras-González
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
| | - Ramón Moreno-Luna
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
- Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital/FISEVI, Seville, Spain
| | - Francisca Palomares
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
| | - José Luis Muñoz-Bravo
- Clinical Analysis Service, General University Hospital of Elche, Foundation for the Promotion of Health and Biomedical Research in the Valencia Region (FISABIO), Elche, Spain
| | - Gonzalo Alba
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
| | - Consuelo Santa-María
- Department of Biochemistry and Molecular Biology, School of Pharmacy, Universidad de Sevilla, Seville, Spain
| | - Juan Maza-Solano
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
- Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital/FISEVI, Seville, Spain
| | - Daniel Iván Martín-Jiménez
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
| | - Antonio Pérez-Pérez
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
| | - Rafael Moreno-Luna
- Pathophysiology and Regenerative Medicine Group, National Paraplegic Hospital, Toledo, Spain
- Cooperative Research Networks aimed at Health Results, Cerebral vascular diseases, RICORS-ICTUS, SESCAM, Toledo, Spain
| | - Víctor Sánchez-Margalet
- Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, Universidad de Sevilla, Seville, Spain
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
| | - Serafín Sánchez-Gómez
- Institute of Biomedicine of Seville (IBiS)/Virgen del Rocío University Hospital/Virgen Macarena University Hospital/University of Seville/CSIC, Seville, Spain
- Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital/FISEVI, Seville, Spain
| |
Collapse
|
2
|
M Yusoff NNF, Ahmad S, Wan Abdul Rahman WF, Mohamud R, C Boer J, Plebanski M, Abdullah B, Chen X, Tengku Din TADAA. CD4+ Foxp3+ Regulatory T-cells in Modulating Inflammatory Microenvironment in Chronic Rhinosinusitis with Nasal Polyps: Progress and Future Prospect. Cytokine 2024; 178:156557. [PMID: 38452440 DOI: 10.1016/j.cyto.2024.156557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 01/26/2024] [Accepted: 02/20/2024] [Indexed: 03/09/2024]
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a subtype of chronic rhinosinusitis (CRS) characterized by the presence of nasal polyps (NP) in the paranasal mucosa. Despite the complex etiology, NP is believed to result from chronic inflammation. The long-term aftermath of the type 2 response is responsible for symptoms seen in NP patients, i.e. rhinorrhea, hyposmia, and nasal obstruction. Immune cellular tolerogenic mechanisms, particularly CD4 + Foxp3 + regulatory T cells (Tregs), are crucial to curtail inflammatory responses. Current evidence suggests impaired Treg activity is the main reason underlying the compromise of self-tolerance, contributing to the onset of CRSwNP. There is compelling evidence that tumor necrosis factor 2 (TNFR2) is preferentially expressed by Tregs, and TNFR2 is able to identify the most potent suppressive subset of Tregs. Tumor necrosis factor (TNF)-TNFR2 interaction plays a decisive role in the activation and expansion of Tregs. This review summarizes current understanding of Tregs biology, focusing on the discussion of the recent advances in the study of TNF-TNFR2 axis in the upregulation of Treg function as a negative feedback mechanism in the control of chronic inflammation. The role of dysregulation of Tregs in the immunopathogenesis of CRSwNP will be analyzed. The future perspective on the harnessing Tregs-mediated self-tolerant mechanism in the management of CRSwNP will be introduced.
Collapse
Affiliation(s)
- Nur Najwa Farahin M Yusoff
- Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Suhana Ahmad
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | | | - Rohimah Mohamud
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
| | - Jennifer C Boer
- Translational Immunology and Nanotechnology Unit, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083, Australia
| | - Magdalena Plebanski
- Translational Immunology and Nanotechnology Unit, School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083, Australia
| | - Baharudin Abdullah
- Department of Otorhinolaryngology-Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
| | - Xin Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China
| | | |
Collapse
|
3
|
Martin-Jimenez D, Moreno-Luna R, Cuvillo A, Gonzalez-Garcia J, Maza-Solano J, Sanchez-Gomez S. Endoscopic Extended Sinus Surgery for Patients with Severe Chronic Rhinosinusitis with Nasal Polyps, the Choice of Mucoplasty: A Systematic Review. Curr Allergy Asthma Rep 2023; 23:733-746. [PMID: 37991673 PMCID: PMC10739272 DOI: 10.1007/s11882-023-01113-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/27/2023] [Indexed: 11/23/2023]
Abstract
PURPOSE OF REVIEW The advances in the knowledge of the molecular basis of the inflammatory response in chronic rhinosinusitis with nasal polyps (CRSwNP) have led the management of these patients towards personalized and precision medicine. Surgery has been positioned as a suitable alternative in patients who do not achieve control with appropriate medical treatment, but polypoid recurrences remain a constraint. The emergence of new surgical approaches based on patient phenotyping and the poor disease control associated with type 2 inflammatory phenotype makes it necessary to review the role of personalized and precision surgery in managing the disease. RECENT FINDINGS Surgical approaches based on wide resection of bony sinus structures and the treatment of mucosa lining the sinonasal cavity have been analyzed and compared with other techniques and seem to offer more favorable surgical outcomes and improved quality of life (QoL), in addition to lower relapse rates. The innovations with new complementary surgical techniques, such as reboot surgery adding an extended autologous mucosal graft from the nasal floor (mucoplasty), may benefit endoscopic and QoL outcomes in the most severe CRSwNP patients with type 2 phenotype. Using bilateral endonasal mucoplasty as a complementary technique to reboot surgery is a suitable technical choice that has improved short- and medium-term QoL and endoscopic outcomes for patients with severe CRSwNP. These results are likely due to a combination of the extension of reboot and the inherent inflammatory and healing properties of mucoplasty. We propose this technique as a valuable surgical resource, although more robust clinical studies are needed to evaluate its long-term benefits comprehensively.
Collapse
Affiliation(s)
- Daniel Martin-Jimenez
- Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain
| | - Ramon Moreno-Luna
- Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain
| | - Alfonso Cuvillo
- Unidad de Rinología y Asma, UGC ORL, Hospital Universitaro De Jerez, Instituto De Investigación Biomedica De Cadiz (INIBICA), Jerez, 11407, Spain
| | - Jaime Gonzalez-Garcia
- Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain
| | - Juan Maza-Solano
- Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain.
- Department of Surgery, University of Seville, C. San Fernando, 4, Sevilla, 41004, Spain.
| | - Serafin Sanchez-Gomez
- Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain
| |
Collapse
|
4
|
Maza-Solano J, Callejon-Leblic A, Martin-Jimenez D, Moreno-Luna R, Gonzalez-Garcia J, Cuvillo A, Sanchez-Gomez S. Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study. Curr Allergy Asthma Rep 2023; 23:555-566. [PMID: 37644255 DOI: 10.1007/s11882-023-01106-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2023] [Indexed: 08/31/2023]
Abstract
PURPOSE OF REVIEW Despite molecular underlying advances, limited and divergent data on monoclonal antibodies (mAb) therapy in chronic rhinosinusitis with nasal polyps (CRSwNP) make further analysis necessary. The objective of this study is to evaluate the effect of omalizumab as an adjunct to endoscopic sinus surgery (ESS) on the treatment of CRSwNP under real-life conditions. RECENT FINDINGS Since the introduction of omalizumab, as the first biologic agent for the treatment of diseases such as severe allergic asthma, different studies have demonstrated an effect of omalizumab on CRSwNP, with significant improvements in sinonasal symptoms and endoscopic scores. The high efficacy derived from mAb therapy and the need for ESS prior to mAb recommended by guidelines, has led to compare both therapeutic alternatives, finding discrepancies in their effect on quality of life (QoL) and complementary tests outcomes. Patients with moderate-to-severe asthma with clinical criteria for omalizumab indication, and coexistent CRSwNP disease, were selected for a non-randomized interventional retrospective study into four treatment subgroups. Measures were analyzed and compared between groups and over time at the baseline, 16 weeks and 1 and 2 years after treatment. Omalizumab treatment in patients with previous ESS exhibited an earlier and more pronounced improvement in QoL, symptoms scale and endoscopic findings (nasal polyp score and the bilateral modified Lund-Kennedy) as early from week 16, which improvement persisted for 2 years. A greater mean improvement of 33.4 ± 6.5 (95% CI: 20.3-46.4; p < 0.001) points in sinonasal outcome test 22 (SNOT-22) was associated with ESS at week 16, against omalizumab effect (17.8 ± 7.6 [95% CI: 2.6-33.0]; p = 0.023). At year 2, an improvement in SNOT-22 of 62.6 ± 8.9 (95% CI: 48.4-84.1; p < 0.001) points was exclusively associated with omalizumab. Clinical evidence of the effect of omalizumab added to ESS treatment is provided in this study in the short- and long-term.
Collapse
Affiliation(s)
- Juan Maza-Solano
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain
| | - Amparo Callejon-Leblic
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain
- Biomedical Engineering Group, University of Seville, Seville, Spain
| | - Daniel Martin-Jimenez
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain.
| | - Ramon Moreno-Luna
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain
| | - Jaime Gonzalez-Garcia
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain
| | - Alfonso Cuvillo
- Rhinology and Asthma Unit, ENT Department, Jerez Hospital, Cadiz, Spain
| | - Serafin Sanchez-Gomez
- Rhinology Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Seville, Spain
| |
Collapse
|